



### Supplemental Figure 1. Effects of T cell Receptor Activation on LPS Survival.

Ten-day survival of wild type C57Bl/6 mice, CD4<sup>-/-</sup> (CD8 T cells only) and CD8<sup>-/-</sup> (CD4 T cells only) mice, TCRab<sup>-/-</sup> mice or C3H/HeJ mice. Seven cohorts studied: control isotype antibody treatment (Iso; 50μg), anti-CD3ε T cell activating antibody treatment (CD3; clone 145-2C11, 50μg), low dose LPS + isotype antibody treatment (LPSLo; 60μg), high dose LPS + isotype antibody treatment (LPSLo; 600μg), CD3 + CpG (CD3CpG; CpG = 50μg), CD3 + PolyI:C (CD3PolyI:C, PolyI:C = 50μg), or CD3 + LPSLo treatment (CD3LPSLo). Significance determined using Spearman's Log-rank test. A. CD3LPSLo, CD3 + CpG or CD3 + PolyI:C C57Bl/6 mice. N=4/group for CD3/CpG and CD3/PolyI:C and N=7/group for CD3LPSLo. B. CD3, LPSLo, and CD3LPSLo CD4<sup>-/-</sup> (CD8 T cells only) and CD8<sup>-/-</sup> (CD4 T cells only) mice. N=5/group. C. LPSHi C57Bl/6 and TCRab<sup>-/-</sup> mice. N=10/group. D. CD3LPSLo C57Bl/6 mice and C3H/HeJ mice. N=10/group.